國網信通(600131.SH)子公司預中標合計1.02億元項目
格隆匯9月29日丨國網信通(600131.SH)公佈,公司全資子公司北京中電普華信息技術有限公司(以下簡稱“中電普華”)、安徽繼遠軟件有限公司(以下簡稱“繼遠軟件”)、四川中電啟明星信息技術有限公司(以下簡稱“中電啟明星”)、北京中電飛華通信有限公司(以下簡稱“中電飛華”)於近日在國家電網有限公司信息化項目2020年第三次服務招標採購和2020年第三次設備招標採購中被推薦為中標候選人。
中電普華、繼遠軟件、中電飛華3家公司在信息化硬件設備、信息安全設備、硬件設備-擴容、視頻會議系統等共計預中標1.02億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.